Aemetis (NASDAQ:AMTX) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Aemetis (NASDAQ:AMTX) announced its earnings results on Thursday. The specialty chemicals company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.06), FiscalAI reports. The firm had revenue of $54.62 million during the quarter, compared to the consensus estimate of $66.70 million.

Here are the key takeaways from Aemetis’ conference call:

• Financial inflection point: Q1 revenue rose 27% YoY to $54.6M, the company returned to positive gross profit ($2.8M) and cut operating loss ~60%, signaling improved underlying margins across all segments.
• LCFS pathway approvals: CARB approved 7 new RNG pathways at an average CI of -380 (vs -150 default) with 6 more nearing approval, which materially increases LCFS credit generation per MMBtu and should boost revenue as production scales.
• Capital projects advancing: Dairy pretreatment skids delivered under a $27M contract and the $40M MVR project at Keyes is under construction with major equipment on-site; management expects MVR commissioning later this year to displace ~80% of plant natural gas and add roughly $32M of annual cash flow.
• India operations & IPO plan: Q1 India biodiesel revenue rebounded to $10.5M, management has retained advisors for an IPO of Universal Biofuels and expects improved, cost‑plus contract pricing and higher utilization to support the offering and expansion funding.
• Financing and 45Z dependency: Large projects (notably the 80M gallon RD/SAF facility) have permits and market interest but financing timing and final economics hinge on the DOE publishing the updated 45Z CF‑GREET calculator and securing long‑term financing, creating near‑term uncertainty.

Aemetis Stock Performance

Shares of AMTX stock traded down $0.12 during trading hours on Thursday, hitting $3.12. 3,111,094 shares of the company were exchanged, compared to its average volume of 1,790,618. Aemetis has a one year low of $1.22 and a one year high of $3.80. The business’s 50-day simple moving average is $2.49 and its two-hundred day simple moving average is $1.98. The stock has a market capitalization of $212.63 million, a price-to-earnings ratio of -2.35 and a beta of 1.46.

Hedge Funds Weigh In On Aemetis

A number of large investors have recently bought and sold shares of AMTX. Marshall Wace LLP lifted its holdings in Aemetis by 289.3% in the fourth quarter. Marshall Wace LLP now owns 559,754 shares of the specialty chemicals company’s stock worth $778,000 after acquiring an additional 415,978 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Aemetis by 15.3% in the third quarter. Vanguard Group Inc. now owns 2,479,163 shares of the specialty chemicals company’s stock worth $5,578,000 after acquiring an additional 329,760 shares during the last quarter. Jane Street Group LLC bought a new position in Aemetis in the second quarter worth about $634,000. CIBC Bancorp USA Inc. bought a new position in Aemetis in the third quarter worth about $563,000. Finally, 683 Capital Management LLC bought a new position in Aemetis in the fourth quarter worth about $327,000. Institutional investors own 27.02% of the company’s stock.

Analyst Upgrades and Downgrades

AMTX has been the topic of several research analyst reports. Ascendiant Capital Markets increased their price target on shares of Aemetis from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, April 8th. Loop Capital set a $1.75 price target on shares of Aemetis in a research report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aemetis in a research report on Monday, April 20th. Finally, Wall Street Zen raised shares of Aemetis from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Aemetis has an average rating of “Hold” and a consensus price target of $8.58.

About Aemetis

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.